Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 6/20 | 0.53 |
| ▸ | STS | P08842 | 4/20 | 0.50 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.49 |
| ▸ | CNR1 | P21554 | 2/20 | 0.48 |
| ▸ | THRA | P10827 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1038708 | 0.93 | HSD17B3 (0.50) | HSD17B3STSPLA2G2AHDAC8HDAC1 | |
| SCHEMBL17694477 | 0.91 | HSD17B3 (0.47) | HSD17B3STSPLA2G2AHDAC8HDAC1 | |
| SCHEMBL5279741 | 0.86 | PDE4B (0.63) | HDAC8HDAC1 | |
| SCHEMBL15338421 | 0.84 | ALDH1A1 (0.44) | HSD17B3STSTHRATHRB | |
| SCHEMBL7315752 | 0.84 | THRA (0.60) | HDAC8HDAC1THRATHRB | |
| SCHEMBL10736335 | 0.84 | THRA (0.60) | HDAC8HDAC1THRATHRB | |
| SCHEMBL4884718 | 0.84 | THRA (0.60) | HDAC8HDAC1THRATHRB | |
| SCHEMBL12016810 | 0.83 | HDAC8 (0.69) | HSD17B3STSHDAC8HDAC1 | |
| SCHEMBL9520347 | 0.83 | HDAC8 (0.69) | HSD17B3STSHDAC8HDAC1 | |
| SCHEMBL9045542 | 0.83 | HDAC8 (0.69) | HSD17B3STSHDAC8HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11964956-B2 | Cannabinergic compounds and uses thereof | NORTHEASTERN UNIVERSITY (US) | 2024-04-23 | — | — | US | disclosed |
| US-20210101878-A1 | Cannabinergic Compounds And Uses Thereof | NORTHEASTERN UNIVERSITY | 2021-04-08 | — | — | US | disclosed |
| US-20210101878-A1 | Cannabinergic Compounds And Uses Thereof | NORTHEASTERN UNIVERSITY | 2021-04-08 | — | — | US | disclosed |
| US-10882838-B2 | Cannabinergic compounds and uses thereof | NORTHEASTERN UNIVERSITY (US) | 2021-01-05 | — | — | US | disclosed |
| US-10882838-B2 | Cannabinergic compounds and uses thereof | NORTHEASTERN UNIVERSITY (US) | 2021-01-05 | — | — | US | disclosed |
| US-20190185443-A1 | Novel Cannabinergic Compounds And Uses Thereof | NORTHEASTERN UNIVERSITY | 2019-06-20 | — | — | US | disclosed |
| US-20190185443-A1 | Novel Cannabinergic Compounds And Uses Thereof | NORTHEASTERN UNIVERSITY | 2019-06-20 | — | — | US | disclosed |
| US-20160108016-A1 | Novel Cannabinergic Compounds and Uses Thereof | NORTHEASTERN UNIVERSITY (US) | 2016-04-21 | — | — | US | disclosed |
| US-20160108016-A1 | Novel Cannabinergic Compounds and Uses Thereof | NORTHEASTERN UNIVERSITY (US) | 2016-04-21 | — | — | US | disclosed |
| WO-2014039042-A1 | NOVEL CANNABINERGIC COMPOUNDS AND USES THEREOF | NORTHEASTERN UNIVERSITY (US) | 2014-03-13 | — | — | WO | disclosed |
| WO-2014039042-A1 | NOVEL CANNABINERGIC COMPOUNDS AND USES THEREOF | NORTHEASTERN UNIVERSITY (US) | 2014-03-13 | — | — | WO | disclosed |
| US-7863313-B2 | Methods for the treatment of inflammatory diseases | CORTICAL PTY LTD (AU) | 2011-01-04 | — | — | US | disclosed |
| US-20100324001-A1 | Novel Methods for the Treatment of Inflammatory Diseases | CORTICAL PTY LTD (AU) | 2010-12-23 | — | — | US | disclosed |
| EP-1611120-A4 | NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES | CORTICAL PTY LTD (AU) | 2008-04-23 | — | — | EP | disclosed |
| US-20070010563-A1 | Novel methods for the treatment of inflammatory diseases | CORTICAL PTY LTD (AU) | 2007-01-11 | — | — | US | disclosed |
| EP-1611120-A1 | NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Cortical Pty Ltd (AU) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004089927-A1 | NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES | CORTICAL PTY LTD (AU) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11964956-B2 | Cannabinergic compounds and uses thereof | CNR2, CNR1, GPR18 | HSD17B3 2795/4885STS 4801/4885PLA2G2A 1745/4885 |
| US-20190185443-A1 | Novel Cannabinergic Compounds And Uses Thereof | CNR2, CNR1, GPR18 | HSD17B3 2957/4885STS 4845/4885PLA2G2A 1667/4885 |
| US-10882838-B2 | Cannabinergic compounds and uses thereof | CNR2, CNR1, GPR18 | HSD17B3 2795/4885STS 4801/4885PLA2G2A 1745/4885 |
| US-20070010563-A1 | Novel methods for the treatment of inflammatory diseases | MIF, CCL2, CCL11 | HSD17B3 610/4885STS 1528/4885PLA2G2A 1439/4885 |
| US-20100324001-A1 | Novel Methods for the Treatment of Inflammatory Diseases | MIF, CCL2, CCL11 | HSD17B3 610/4885STS 1528/4885PLA2G2A 1439/4885 |
| US-20210101878-A1 | Cannabinergic Compounds And Uses Thereof | CNR2, CNR1, GPR18 | HSD17B3 2795/4885STS 4801/4885PLA2G2A 1745/4885 |
| US-20160108016-A1 | Novel Cannabinergic Compounds and Uses Thereof | CNR2, CNR1, GPR18 | HSD17B3 2957/4885STS 4845/4885PLA2G2A 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.